{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:02:22Z","timestamp":1762999342073,"version":"3.38.0"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The immunoregulatory and anti-infective properties of normal circulating polyclonal Abs have been exploited for the therapeutic purposes in the form of IVIG as well as several hyperimmune globulins. Current knowledge on the therapeutic use of normal Igs is based on the discoveries made by several pioneers of the field. In this paper, we review the evolution of IVIG over the years. More importantly, the process started as an s.c. replacement in \u03b3 globulin\u2013deficient patients, underwent metamorphosis into i.m. Ig, was followed by IVIG, and is now back to s.c. forms. Following successful use of IVIG in immune thrombocytopenic purpura, there has been an explosion in the therapeutic applications of IVIG in diverse autoimmune and inflammatory conditions. In addition to clinically approved pathological conditions, IVIG has been used as an off-label drug in more than 100 different indications. The current worldwide consumption of IVIG is over 100 tons per year.<\/jats:p>","DOI":"10.4049\/jimmunol.1701271","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T21:40:14Z","timestamp":1520286014000},"page":"1957-1963","source":"Crossref","is-referenced-by-count":24,"title":["Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies"],"prefix":"10.1093","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-766X","authenticated-orcid":false,"given":"Cristina","family":"Jo\u00e3o","sequence":"first","affiliation":[{"name":"Hematology Department, Champalimaud Center for the Unknown , Lisbon 1400-038,","place":["Portugal"]},{"name":"Immunology Department, Nova Medical School, Nova University of Lisbon , Lisbon 1169-056,","place":["Portugal"]}]},{"given":"Vir Singh","family":"Negi","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research , Puducherry 605006,","place":["India"]}]},{"given":"Michel D","family":"Kazatchkine","sequence":"additional","affiliation":[{"name":"United Nations Special Envoy for AIDS in Eastern Europe and Central Asia , Geneva CH-1211,","place":["Switzerland"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-9808","authenticated-orcid":false,"given":"Jagadeesh","family":"Bayry","sequence":"additional","affiliation":[{"name":"INSERM Unit\u00e9 1138 , Paris F-75006,","place":["France"]},{"name":"Sorbonne Universit\u00e9, UMR S 1138 , Paris F-75006,","place":["France"]},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, UMR S 1138 , Paris F-75006,","place":["France"]},{"name":"Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immuno-Intervention Th\u00e9rapeutique , Paris F-75006,","place":["France"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-4053","authenticated-orcid":false,"given":"Srini V","family":"Kaveri","sequence":"additional","affiliation":[{"name":"INSERM Unit\u00e9 1138 , Paris F-75006,","place":["France"]},{"name":"Sorbonne Universit\u00e9, UMR S 1138 , Paris F-75006,","place":["France"]},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, UMR S 1138 , Paris F-75006,","place":["France"]},{"name":"Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immuno-Intervention Th\u00e9rapeutique , Paris F-75006,","place":["France"]}]}],"member":"286","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"2025030610140290900_r1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.1.4863.668","article-title":"Emil von Behring, born March 15, 1854","volume":"1","author":"MacNalty","year":"1954","journal-title":"Br. Med. J."},{"key":"2025030610140290900_r2","first-page":"384","article-title":"Contribution \u00e0 l\u2019\u00e9tude de la diphth\u00e9rie. 3e m\u00e9moire","volume":"4","author":"Roux","year":"1890","journal-title":"Ann. Inst. Pasteur (Paris)"},{"volume-title":"Search of a Cure.","year":"1999","author":"Weatheral","key":"2025030610140290900_r3"},{"key":"2025030610140290900_r4","first-page":"437","article-title":"\u2018On immunity with special reference to cell life\u2019. Royal society croonian lecture","volume":"66","author":"Ehrlich","year":"1900","journal-title":"Roy. Soc. Proc."},{"key":"2025030610140290900_r5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(05)79625-2","article-title":"The noble chronicles","volume":"352","author":"Raju","year":"1998","journal-title":"Lancet"},{"key":"2025030610140290900_r6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/j150358a015","article-title":"The chemistry of antigens and antibodies","volume":"38","author":"Marrack","year":"1934","journal-title":"J. Phys. Chem."},{"key":"2025030610140290900_r7","first-page":"817","article-title":"Injections r\u00e9p\u00e9t\u00e9es de serum de cheval chez le lapin","volume":"55","author":"Arthus","year":"1903","journal-title":"C. R. Seances Soc. Biol. Fil."},{"key":"2025030610140290900_r8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.55.1.163","article-title":"The arthus phenomenon: local anaphylactic inflammation in the rabbit brain","volume":"55","author":"Davidoff","year":"1932","journal-title":"J. Exp. Med."},{"key":"2025030610140290900_r9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1084\/jem.122.1.83","article-title":"Pathogenic factors in vasular lesions of experimental serum sickness","volume":"122","author":"Kniker","year":"1965","journal-title":"J. Exp. Med."},{"key":"2025030610140290900_r10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/genetics\/143.2.621","article-title":"A metabolic basis for dominance and recessivity","volume":"143","author":"Keightley","year":"1996","journal-title":"Genetics"},{"key":"2025030610140290900_r11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1365-2141.2002.03675.x","article-title":"Red cell agglutination: the first description by Creite (1869) and further observations made by Landois (1875) and Landsteiner (1901)","volume":"119","author":"Hughes-Jones","year":"2002","journal-title":"Br. J. Haematol."},{"key":"2025030610140290900_r12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/biot.200500037","article-title":"Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety","volume":"1","author":"Buchacher","year":"2006","journal-title":"Biotechnol. J."},{"key":"2025030610140290900_r13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"2025030610140290900_r14","first-page":"163","article-title":"Hypogammaglobulinaemia in the United Kingdom. Summary report of a medical research council working-party","volume":"1","year":"1969","journal-title":"Lancet"},{"key":"2025030610140290900_r15","first-page":"3","volume-title":"Igs: Biological Aspects and Clinical Uses.","author":"Janeway","year":"1970"},{"key":"2025030610140290900_r16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J. Am. Chem. Soc."},{"key":"2025030610140290900_r17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","article-title":"The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma","volume":"71","author":"Oncley","year":"1949","journal-title":"J. Am. Chem. Soc."},{"key":"2025030610140290900_r18","first-page":"71","article-title":"The preparation of plasmin treated immune serum globulin for intravenous use","volume":"13","author":"Sgouris","year":"1967","journal-title":"Vox Sang."},{"key":"2025030610140290900_r19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1042\/bj1060829","article-title":"Reaction of beta-propiolactone with amino acids and its specificity for methionine","volume":"106","author":"Taubman","year":"1968","journal-title":"Biochem. J."},{"key":"2025030610140290900_r20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2008.06.002","article-title":"Intravenous immunoglobulins: evolution of commercial IVIG preparations","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"2025030610140290900_r21","doi-asserted-by":"crossref","first-page":"78S","DOI":"10.1592\/phco.2005.25.11part2.78S","article-title":"The product: all intravenous immunoglobulins are not equivalent","volume":"25","author":"Siegel","year":"2005","journal-title":"Pharmacotherapy"},{"key":"2025030610140290900_r22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney--a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"2025030610140290900_r23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"2025030610140290900_r24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0736-5748(02)00109-0","article-title":"Proline induces oxidative stress in cerebral cortex of rats","volume":"21","author":"Delwing","year":"2003","journal-title":"Int. J. Dev. Neurosci."},{"key":"2025030610140290900_r25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0003-9861(60)90046-1","article-title":"The precipitation of plasma proteins by short-chain fatty acids","volume":"89","author":"Chanutin","year":"1960","journal-title":"Arch. Biochem. Biophys."},{"key":"2025030610140290900_r26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","article-title":"Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography","volume":"84","author":"Lebing","year":"2003","journal-title":"Vox Sang."},{"key":"2025030610140290900_r27","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial","volume":"3","author":"Roifman","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"2025030610140290900_r28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(83)90496-8","article-title":"Non-A, non-B hepatitis from intravenous immunoglobulin","volume":"2","author":"Lane","year":"1983","journal-title":"Lancet"},{"key":"2025030610140290900_r29","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0140-6736(84)91506-X","article-title":"Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin","volume":"2","author":"Lever","year":"1984","journal-title":"Lancet"},{"key":"2025030610140290900_r30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2014.00665","article-title":"Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy","volume":"5","author":"Farrugia","year":"2014","journal-title":"Front. Immunol."},{"key":"2025030610140290900_r31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1537-2995.1995.35595259143.x","article-title":"Inactivation and removal of blood-borne viruses","volume":"35","author":"Vyas","year":"1995","journal-title":"Transfusion"},{"key":"2025030610140290900_r32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1423-0410.2003.00279.x","article-title":"Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process","volume":"84","author":"Trejo","year":"2003","journal-title":"Vox Sang."},{"key":"2025030610140290900_r33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.0042-9007.2004.00515.x","article-title":"Removal of small non-enveloped viruses by nanofiltration","volume":"86","author":"Yokoyama","year":"2004","journal-title":"Vox Sang."},{"key":"2025030610140290900_r34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","article-title":"Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion","volume":"338","author":"Gardulf","year":"1991","journal-title":"Lancet"},{"key":"2025030610140290900_r35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s10875-011-9557-z","article-title":"Efficacy and safety of hizentra\u00ae, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency","volume":"31","author":"Borte","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"2025030610140290900_r36","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10875-016-0327-9","article-title":"Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America","volume":"36","author":"Suez","year":"2016","journal-title":"J. Clin. Immunol."},{"key":"2025030610140290900_r37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biologicals.2009.09.002","article-title":"L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions","volume":"38","author":"Bolli","year":"2010","journal-title":"Biologicals"},{"key":"2025030610140290900_r38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030610140290900_r39","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2016-0066","article-title":"Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability","volume":"8","author":"Wasserman","year":"2016","journal-title":"Immunotherapy"},{"key":"2025030610140290900_r40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"2025030610140290900_r41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1503\/cmaj.130375","article-title":"Intravenous immunoglobulin as clinical immune-modulating therapy","volume":"187","author":"Gilardin","year":"2015","journal-title":"CMAJ"},{"key":"2025030610140290900_r42","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025030610140290900_r43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/08916930902785363","article-title":"Intravenous immunoglobulin therapy for autoimmune diseases","volume":"42","author":"Arnson","year":"2009","journal-title":"Autoimmunity"},{"key":"2025030610140290900_r44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"2025030610140290900_r45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.molmed.2015.01.005","article-title":"Molecular and immunological biomarkers to predict IVIg response","volume":"21","author":"Galeotti","year":"2015","journal-title":"Trends Mol. Med."},{"key":"2025030610140290900_r46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ncpneuro0429","article-title":"Shortage of human intravenous immunoglobulin--reasons and possible solutions","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"2025030610140290900_r47","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/eji.201444700","article-title":"European consensus proposal for immunoglobulin therapies","volume":"44","author":"Sewell","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"2025030610140290900_r48","first-page":"CD004429","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"2","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"2025030610140290900_r49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"2025030610140290900_r50","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"2025030610140290900_r51","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"1","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"2025030610140290900_r52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"2025030610140290900_r53","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"2025030610140290900_r54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(85)90400-3","article-title":"Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood","volume":"2","author":"Imbach","year":"1985","journal-title":"Lancet"},{"key":"2025030610140290900_r55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","article-title":"The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials","volume":"21","author":"Qin","year":"2010","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"2025030610140290900_r56","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1034\/j.1600-6143.2002.20809.x","article-title":"Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg)","volume":"2","author":"Glotz","year":"2002","journal-title":"Am. J. Transplant."},{"key":"2025030610140290900_r57","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"2025030610140290900_r58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"2025030610140290900_r59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11533290-000000000-00000","article-title":"Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety","volume":"11","author":"G\u00fcrcan","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"2025030610140290900_r60","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"2025030610140290900_r61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1084\/jem.20061788","article-title":"The antiinflammatory activity of IgG: the intravenous IgG paradox","volume":"204","author":"Nimmerjahn","year":"2007","journal-title":"J. Exp. Med."},{"key":"2025030610140290900_r62","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"2025030610140290900_r63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cei.1996.104.s1.21","article-title":"Modulation of complement-mediated immune damage by intravenous immune globulin","volume":"104","author":"Basta","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"2025030610140290900_r64","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J. Immunol."},{"key":"2025030610140290900_r65","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.autrev.2008.03.015","article-title":"Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg)","volume":"7","author":"von Gunten","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"2025030610140290900_r66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"2025030610140290900_r67","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"2025030610140290900_r68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2006-05-023796","article-title":"A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?","volume":"109","author":"Crow","year":"2007","journal-title":"Blood"},{"key":"2025030610140290900_r69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int. Immunol."},{"key":"2025030610140290900_r70","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"2025030610140290900_r71","doi-asserted-by":"crossref","first-page":"E2385","DOI":"10.1073\/pnas.1505292112","article-title":"Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs","volume":"112","author":"Fiebiger","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030610140290900_r72","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0091-6749(99)70466-5","article-title":"Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin","volume":"103","author":"Spahn","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Supplement_1","key":"2025030610140290900_r73","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1007\/s10875-010-9394-5","article-title":"Immunomodulation by intravenous immunoglobulin: role of regulatory T cells","volume":"30","author":"Maddur","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"2025030610140290900_r74","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J. Immunol."},{"key":"2025030610140290900_r75","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.111123","article-title":"Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease","volume":"39","author":"Bayry","year":"2012","journal-title":"J. Rheumatol."},{"key":"2025030610140290900_r76","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2012-11-468264","article-title":"Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells","volume":"122","author":"Trinath","year":"2013","journal-title":"Blood"},{"key":"2025030610140290900_r77","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/cei.12102","article-title":"Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells","volume":"173","author":"Tjon","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"2025030610140290900_r78","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/cmi.2014.117","article-title":"Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation","volume":"12","author":"Maddur","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"2025030610140290900_r79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00431-013-1937-3","article-title":"Lack of CD4+CD25+FOXP3+ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease","volume":"172","author":"Hirabayashi","year":"2013","journal-title":"Eur. J. Pediatr."},{"key":"2025030610140290900_r80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12974-017-0818-5","article-title":"Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy","volume":"14","author":"Maddur","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"2025030610140290900_r81","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2012.08.017","article-title":"Tregitope update: mechanism of action parallels IVIg","volume":"12","author":"Cousens","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"2025030610140290900_r82","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaci.2013.09.029","article-title":"Dendritic cell immunoreceptor: a novel receptor for intravenous Ig mediates induction of regulatory T cells","volume":"133","author":"Massoud","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030610140290900_r83","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.it.2017.08.008","article-title":"Circulating normal IgG as stimulator of regulatory T cells: lessons from intravenous immunoglobulin","volume":"38","author":"Maddur","year":"2017","journal-title":"Trends Immunol."},{"key":"2025030610140290900_r84","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaci.2010.12.1102","article-title":"Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous Ig","volume":"127","author":"Maddur","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030610140290900_r85","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/all.12558","article-title":"Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease","volume":"70","author":"Guo","year":"2015","journal-title":"Allergy"},{"key":"2025030610140290900_r86","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.autrev.2011.02.007","article-title":"Comparison of different IVIg preparations on IL-17 production by human Th17 cells","volume":"10","author":"Maddur","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"2025030610140290900_r87","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.4049\/jimmunol.1201965","article-title":"Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis","volume":"190","author":"Othy","year":"2013","journal-title":"J. Immunol."},{"key":"2025030610140290900_r88","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.4049\/jimmunol.172.8.4709","article-title":"B cell-dependent TCR diversification","volume":"172","author":"Jo\u00e3o","year":"2004","journal-title":"J. Immunol."},{"key":"2025030610140290900_r89","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/eji.200635908","article-title":"Immunoglobulin promotes the diversity and the function of T cells","volume":"36","author":"Jo\u00e3o","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"2025030610140290900_r90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaci.2013.08.042","article-title":"Intravenous Ig induces a functional silencing program similar to anergy in human B cells","volume":"133","author":"Seite","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030610140290900_r91","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2002-06-1684","article-title":"Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG","volume":"101","author":"de Grandmont","year":"2003","journal-title":"Blood"},{"key":"2025030610140290900_r92","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clim.2010.01.001","article-title":"Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg)","volume":"135","author":"Paquin Proulx","year":"2010","journal-title":"Clin. Immunol."},{"key":"2025030610140290900_r93","doi-asserted-by":"crossref","first-page":"1036.e1","DOI":"10.1016\/j.amjmed.2012.01.023","article-title":"Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections","volume":"125","author":"Ferrara","year":"2012","journal-title":"Am. J. Med."},{"key":"2025030610140290900_r94","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.chom.2016.10.018","article-title":"Tackling difficult Staphylococcus aureus infections: antibodies show the way","volume":"20","author":"Shopsin","year":"2016","journal-title":"Cell Host Microbe"},{"key":"2025030610140290900_r95","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood.V90.10.4004","article-title":"Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease","volume":"90","author":"Hurez","year":"1997","journal-title":"Blood"},{"key":"2025030610140290900_r96","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.39142","article-title":"Reversal of rrthritis by human monomeric IgA through the receptor-mediated SH2 domain-containing phosphatase 1 inhibitory pathway","volume":"67","author":"Rossato","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"2025030610140290900_r97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fimmu.2017.00275","article-title":"Monomeric immunoglobulin A from plasma inhibits human Th17 responses in vitro independent of Fc\u03b1RI and DC-SIGN","volume":"8","author":"Saha","year":"2017","journal-title":"Front. Immunol."},{"key":"2025030610140290900_r98","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"2025030610140290900_r99","first-page":"E1297","article-title":"Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. [Published erratum appears in 2015 Proc. Natl. Acad. Sci. USA 112: E4339.]","volume":"112","author":"Washburn","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030610140290900_r100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri3401-c1","article-title":"IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist","volume":"14","author":"von Gunten","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"2025030610140290900_r101","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3324\/haematol.2015.136739","article-title":"The European hematology association roadmap for European hematology research: a consensus document","volume":"101","author":"Engert","year":"2016","journal-title":"Haematologica"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/200\/6\/1957\/61513268\/ji1701271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/200\/6\/1957\/61513268\/ji1701271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:30:12Z","timestamp":1741257012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/200\/6\/1957\/7962473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,3,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1701271","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,3]]}}}